Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PGN EDODM1

Next Previous
X
Search
Drug Profile

PGN EDODM1

Alternative Names: EDODM1; PGN-EDODM1

Latest Information Update: 16 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pepgen Corporation
  • Class Antisense oligonucleotides; Drug conjugates; Morpholines; Peptide drug conjugates
  • Mechanism of Action RNA interference; RNA splicing modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myotonic dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Myotonic dystrophy

Most Recent Events

  • 08 Aug 2024 Health Canada and the United Kingdom Medicines and Healthcare products Regulatory Agency approves Clinical trial application (CTA) for the FREEDOM2 trial of PGN EDODM1 in Myotonic dystrophy type 1 (DM1)
  • 08 Aug 2024 PepGen plans a phase II FREEDOM2-DM1 trial in Myotonic dystrophy type 1 in Canada, the UK, and in the US, subject to regulatory clearance, in the second half of 2024
  • 06 Mar 2024 Phase-I clinical trials in Myotonic dystrophy in USA, and United Kingdom (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top